The company plans to grow its network of radiopharmacy partners to more than 40 sites over the first half of 2017. Ten radiopharmacies are currently in operation, with three more expected to become active shortly. are now delivering more than 120 patient-ready doses of NETSPOTВ® in injection form per month. AAA and its radiopharmacy partners around the U.S. NETSPOTВ® is available in two forms: As a drug kit for reconstitution using a Ga68 generator, and as a ready-to-use injection delivered from local radiopharmacies in select metropolitan areas. The product has been used and paid for over the past six months, even prior to the issuance of this Pass-Through code, demonstrating recognition of NETSPOTвЂ™sВ® value to NET patient management. Food and Drug Administration (вЂњFDAвЂќ) in June 2016 for the preparation of gallium Ga 68 dotatate for injection, for the localization of somatostatin receptor positive neuroendocrine tumors (вЂњNETsвЂќ) in adult and pediatric patients using Positron Emission Tomography (вЂњPETвЂ™).ДЄ first-in-class drug, NETSPOTВ® was approved after a record-breaking 23 months from the first pre-Investigational New Drug meeting with the FDA.

Additionally, the same Healthcare Common Procedure Coding System (вЂњHCPCSвЂќ) вЂњACodeвЂќ will be used on claims to private payers. (NASDAQ:AAAP) (вЂњAAAвЂќ or вЂњthe CompanyвЂќ), an international specialist in Molecular Nuclear Medicine (вЂњMNMвЂќ), today announced that the Centers for Medicare & Medicaid Services (CMS) has granted NETSPOTВ® Transitional Pass-Through status under an вЂњA-codeвЂќ (A9587) for drug reimbursement, effective January 1, 2017.

Netspot fda